A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

NCT06755515 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ENROLLING_BY_INVITATION

Status

510

Enrollment

INDUSTRY

Sponsor class

Conditions

Cervical Cancer

Interventions

DRUG: Rulonilimab
DRUG: Placebo
DRUG: cisplatin/carboplatin + paclitaxel ± bevacizumab

Sponsor

Shandong New Time Pharmaceutical Co., LTD